Radiopharm advances RAD101 toward pivotal brain imaging trial

RAD101 clears FDA milestone ahead of Phase 3

Radiopharm Theranostics (ASX:RAD, Nasdaq:RADX) has moved its lead imaging asset toward a pivotal trial, saying RAD101 is expected to enter Phase 3 in the first quarter of 2027 after a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration. The trial will assess the fluorine-18-labelled small molecule in people with recurrent brain metastases from solid tumours.

The regulatory progress builds on Phase 2b results in which RAD101 recorded 93% concordance with MRI across all evaluable lesions, meeting the study’s primary endpoint. The company is also due to present interim data at the Society of Neuro-Oncology’s annual meeting in November, while Siemens Healthineers is set to manufacture and distribute RAD101 doses for the planned US registrational trial. The earlier FDA meeting milestone had been described as providing a framework for the next stage, although the filing now supplies the more concrete Phase 3 timing.

Several early-stage programmes keep moving

RAD101 is not the only clinical programme advancing. RAD202 reached its fourth Phase 1 dosing cohort at 180mCi in the HEAT study of HER2-positive advanced solid tumours, following a positive recommendation from its Data Safety and Monitoring Committee. RAD204 continued dosing in its 90mCi third cohort across PD-L1-driven cancers, with cohort data intended to inform a future Phase 2 dose.

Radiopharm also reported positive Phase 1 imaging data for RAD301 in pancreatic ductal adenocarcinoma. The company said all evaluable participants showed a favourable safety profile, with favourable biodistribution and significant tumour uptake in pancreatic cancer metastases. That result supports continued development of the imaging agent and the potential for a future therapeutic pairing, but remains an early clinical finding rather than evidence of patient benefit.

In its Radiopharm Ventures joint venture with MD Anderson Cancer Center, the company dosed the first patient in the second cohort of the RV-01 Phase 1/2 study at 70mCi. The trial is designed to assess safety, biodistribution, radiation dosimetry and preliminary anti-tumour activity in B7-H3-expressing tumours. Radiopharm subsequently increased its ownership of the venture from 87.5% to 93.75%.

Cash position remains the immediate constraint

The quarter’s clinical momentum was funded at a substantial cash cost. Net operating cash outflow was A$10.687 million, including A$11.930 million of research and development payments and A$3.875 million in staff costs. Government grants and tax incentives contributed A$5.984 million, including the company’s A$5.885 million R&D tax refund for the 2025 financial year.

Radiopharm ended September with A$7.462 million in cash, compared with A$4.137 million at the end of the prior quarter, after recording A$14.920 million in equity proceeds and A$798,000 of associated transaction costs. The Appendix 4C therefore calculates estimated funding at 0.70 quarters based on quarter-end cash and the latest operating outflow. That figure excludes the A$8 million received after quarter end from Rockford Capital under a facility secured against the anticipated FY26 R&D tax incentive, an advance also reported in the R&D tax incentive advance.

The filing says the board is assessing further equity and non-dilutive funding, while cash-management measures may include delaying discretionary operating activities. It also says the company expects near-term operating outflows to remain broadly consistent with the A$10.7 million recorded in the quarter, although spending may vary with clinical timing. One detail will need clarification: the narrative refers to a A$12.5 million institutional placement and a A$3 million share purchase plan, while the opening update refers to a A$6 million SPP. The reported A$14.92 million of equity proceeds does not resolve that discrepancy.

Phase 3 preparation now meets funding test

Radiopharm has assembled a more mature clinical narrative around RAD101, with an FDA meeting completed, a planned Phase 3 start and manufacturing support in place. The company’s other assets are producing incremental safety, imaging and dose-escalation data, but most remain in Phase 1 development and still require further clinical evidence.

The next test is therefore twofold: whether the November RAD101 presentation and subsequent trial preparation preserve the lead programme’s momentum, and whether the company can fund that work without repeatedly leaning on dilutive equity or secured advances. The A$8 million facility improves the immediate cash position, but its effect on the financing timetable will depend on the pace of clinical spending and the terms of future capital sources.